Correction to: A phase I study of inotuzumab ozogamicin as a single agent in pediatric patients in Japan with relapsed/refractory CD22-positive acute lymphoblastic leukemia (INO-Ped-ALL-1)

Int J Hematol. 2023 May;117(5):786. doi: 10.1007/s12185-023-03584-0.

Hideki Nakayama¹, Chitose Ogawa², Masahiro Sekimizu^{3

4}, Hiroyuki Fujisaki⁵, Yoshiyuki Kosaka⁶, Hiroya Hashimoto^{3

7}, Akiko M Saito³, Keizo Horibe^{3

4}

¹ Department of Pediatrics, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan. hnkym415@gmail.com.
² Department of Pediatric Oncology, National Cancer Center Hospital, Tokyo, Japan.
³ Clinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
⁴ Department of Pediatrics, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
⁵ Department of Pediatric Hematology/Oncology, Osaka City General Hospital, Osaka, Japan.
⁶ Department of Hematology and Oncology, Hyogo Prefectural Kobe Children's Hospital, Kobe, Japan.
⁷ Core Laboratory, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan.

No abstract available

Publication types